Data needed for developing and monitoring policies

International Journal of Risk and Safety in Medicine

Volumn 15, Issue 1-2, 2002, Pages 15-27

  Mossialos, Elias ^a   Mrazek, Monique F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; DATA ANALYSIS; DEMOGRAPHY; DRUG CLASSIFICATION; DRUG COST; DRUG INDUSTRY; DRUG MONITORING; DRUG PREFERENCE; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; INTERMETHOD COMPARISON; PHARMACEUTICAL CARE; PRESCRIPTION; PROSPECTIVE PRICING; QUALITY OF LIFE; RELIABILITY; RESOURCE ALLOCATION; REVIEW; VALIDATION PROCESS;

EID: 0036966055     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. C.P. Bradley, Decision making and prescribing patterns - a literature review, Family Practice 8(3) (1991), 276-287.
2. D. Capella, Descriptive tools and analysis, in: Drug Utilization Studies: Methods and Uses, M.N.G. Dukes, ed., World Health Organization, Copenhagen, 1993.
3. Danish Association of the Pharmaceutical Industry, Facts and Figures, Danish Association of the Pharmaceutical Industry (LIF), Copenhagen, 2001.
4. P.M. Danzon and J.D. Kim, International price comparisons for pharmaceuticals: Measurement and policy issues, Pharmacoeconomics 14(Suppl. 1) (1998), 115-128.
5. M.F. Drummond, B. O'Brian, G.L. Stoddart and G.W. Torrance, Methods for the Economic Evaluation of Health Care Programmes, 2nd edn, Oxford Medical Publications, Oxford, 1997.
6. M.F. Drummond, Experimental versus observational data in the economic evaluation of pharmaceuticals, Medical Decision Making 18(2) (Suppl. 1) (1998), S12-S18.
7. A. Earl-Slater and C. Bradley, The Inexorable rise in the UK NHS drugs bill: Recent policies, future prospects, Public Administration 74 (1996), 393-411.
8. A.M. Garber, Advances in CE analysis, in: Handbook of Health Economics, J.P. Newhouse and A.J. Culyer, eds, Vol. 1A, North-Holland, New York, 2000.
9. M.R. Gold et al., Identifying and valuing outcomes, in: Cost-Effectiveness in Health and Medicine, M.R. Gold, J.E. Siegel, L.B. Russell and M.C. Weinstein, eds, Oxford University Press, Oxford, 1996.
10. F.M. Haaijer-Ruskamp and L.T.W. de Jong-van den Berg, Drug utilisation studies and drug monitoring in the Netherlands, Annali Dell Instituto Superiore Di Sanita 27 (1991), 217-223.
11. B. Jonsson, Pricing and reimbursement of pharmaceuticals in Sweden, Pharmacoeconomics 6(Suppl. 1) (1994), 51-60.
12. P. Kanavos and E. Mossialos, International comparisons of health care expenditures: What we know and what we do not know, Journal of Health Services Research and Policy 4(2) (1999), 122-126.
13. T. Lecomte and V. Paris, Consommation de pharmacie en Europe, 1992: Allemagne, France, Italie, Royaume-Uni, No 1048, Paris, Credes, 1994.
14. D.C.E.F. Lloyd, C.M. Harris and D.J. Roberts, Specific therapeutic group age-sex related prescribing units (STAR-PUs): weightings for analysing general practices' prescribing in England, British Medical Journal 311 (1995), 911-994.
15. J.S. Mandelblatt et al., Assessing the effectiveness of health interventions, in: Cost-Effectiveness in Health and Medicine, M.R. Gold, J.E. Siegel, L.B. Russell and M.C. Weinstein, eds, Oxford University Press, Oxford, 1996.
16. OECD, OECD Health Data 2000, OECD, Paris, 2000.
17. L. Payer, Medicine and Culture, Henry Holt, New York, 1996.
18. W.A. Ray, Policy and program analysis using administrative databases, Annals of Internal Medicine 127(8 Pt 2) (1997), 712-718.
19. World Health Organization, Guidelines for ATC classification and DDD Assignment, 2nd edn, WHO Collaborating Centre for Drug Statistic Methodology, Oslo, 1998.
20. WHO Expert Committee, The Selection of Essential Drugs, Technical Report Series No. 615, World Health Organization, Geneva, from 1977, continuing.